Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma.

Castro M, Rabe KF, Corren J, Pavord ID, Katelaris CH, Tohda Y, Zhang B, Rice MS, Maroni J, Rowe P, Pirozzi G, Amin N, Ruddy M, Akinlade B, Graham NMH, Teper A.

ERJ Open Res. 2020 Jan 27;6(1). pii: 00204-2019. doi: 10.1183/23120541.00204-2019. eCollection 2020 Jan.

2.

Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.

Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S, Kawashima M, Ferrándiz C, Smith CH, Beck LA, Chan KC, Chen Z, Akinlade B, Hultsch T, Staudinger H, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Ardeleanu M.

JAMA Dermatol. 2019 Dec 26. doi: 10.1001/jamadermatol.2019.3617. [Epub ahead of print]

3.

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.

Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, Beck LA, Guttman-Yassky E, Pariser D, Blauvelt A, Weisman J, Lockshin B, Hultsch T, Zhang Q, Kamal MA, Davis JD, Akinlade B, Staudinger H, Hamilton JD, Graham NMH, Pirozzi G, Gadkari A, Eckert L, Stahl N, Yancopoulos GD, Ruddy M, Bansal A.

JAMA Dermatol. 2019 Nov 6. doi: 10.1001/jamadermatol.2019.3336. [Epub ahead of print]

4.

Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.

Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, Zhang Y, Zhu X, Chen Z, Li M, Ardeleanu M, Teper A, Akinlade B, Gadkari A, Eckert L, Kamal MA, Ruddy M, Graham NMH, Pirozzi G, Stahl N, DiCioccio AT, Bansal A.

Br J Dermatol. 2020 Jan;182(1):85-96. doi: 10.1111/bjd.18476. Epub 2019 Oct 8.

5.

Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.

Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M, Schoepfer AM, Safroneeva E, Rothenberg ME, Falk GW, Assouline-Dayan Y, Zhao Q, Chen Z, Swanson BN, Pirozzi G, Mannent L, Graham NMH, Akinlade B, Stahl N, Yancopoulos GD, Radin A.

Gastroenterology. 2020 Jan;158(1):111-122.e10. doi: 10.1053/j.gastro.2019.09.042. Epub 2019 Oct 5.

6.

Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.

Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M.

J Am Acad Dermatol. 2020 Feb;82(2):377-388. doi: 10.1016/j.jaad.2019.07.074. Epub 2019 Jul 30.

7.

Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).

Thaçi D, L Simpson E, Deleuran M, Kataoka Y, Chen Z, Gadkari A, Eckert L, Akinlade B, Graham NMH, Pirozzi G, Ardeleanu M.

J Dermatol Sci. 2019 May;94(2):266-275. doi: 10.1016/j.jdermsci.2019.02.002. Epub 2019 Mar 12.

8.

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis.

Eichenfield LF, Bieber T, Beck LA, Simpson EL, Thaçi D, de Bruin-Weller M, Deleuran M, Silverberg JI, Ferrandiz C, Fölster-Holst R, Chen Z, Graham NMH, Pirozzi G, Akinlade B, Yancopoulos GD, Ardeleanu M.

Am J Clin Dermatol. 2019 Jun;20(3):443-456. doi: 10.1007/s40257-019-00445-7.

9.

Conjunctivitis in dupilumab clinical trials.

Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A.

Br J Dermatol. 2019 Sep;181(3):459-473. doi: 10.1111/bjd.17869. Epub 2019 May 7.

10.

Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.

Silverberg JI, Simpson EL, Ardeleanu M, Thaçi D, Barbarot S, Bagel J, Chen Z, Eckert L, Chao J, Korotzer A, Rizova E, Rossi AB, Lu Y, Graham NMH, Hultsch T, Pirozzi G, Akinlade B.

Br J Dermatol. 2019 Jul;181(1):80-87. doi: 10.1111/bjd.17791. Epub 2019 Apr 11.

11.

Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.

Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbé A, Nelson L, Clark M, Williams N, Chen Z, Ardeleanu M, Akinlade B, Graham NMH, Pirozzi G, Staudinger H, Plaum S, Radin A, Gadkari A.

Br J Dermatol. 2019 Oct;181(4):761-769. doi: 10.1111/bjd.17744. Epub 2019 May 1.

12.

Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis.

Blauvelt A, Simpson EL, Tyring SK, Purcell LA, Shumel B, Petro CD, Akinlade B, Gadkari A, Eckert L, Graham NMH, Pirozzi G, Evans R.

J Am Acad Dermatol. 2019 Jan;80(1):158-167.e1. doi: 10.1016/j.jaad.2018.07.048. Epub 2018 Aug 6.

13.

Assessment of cartesian co-ordinates-based bladder and rectal dose and variability with tandem-ring angles first Nigerian experience in high-dose-rate brachytherapy.

Oyekunle EO, Ibhade R, Akinlade BI.

Br J Radiol. 2018 Nov;91(1091):20180258. doi: 10.1259/bjr.20180258. Epub 2018 Aug 13.

14.

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.

Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, Chao J, Staudinger H, Pirozzi G, Antoni C, Amin N, Ruddy M, Akinlade B, Graham NMH, Stahl N, Yancopoulos GD, Teper A.

N Engl J Med. 2018 Jun 28;378(26):2475-2485. doi: 10.1056/NEJMoa1804093. Epub 2018 May 21.

15.

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.

Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A.

N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.

16.

Study of the relationships between brachytherapy plan parameters in an attempt to verify total dwell time in vaginal cylinder applications.

Oyekunle EO, Akinlade BI, Jimoh MA.

J Appl Clin Med Phys. 2018 Jul;19(4):68-74. doi: 10.1002/acm2.12341. Epub 2018 May 13.

17.

Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.

Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A.

Adv Ther. 2018 May;35(5):737-748. doi: 10.1007/s12325-018-0702-4. Epub 2018 May 3.

18.

Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab.

Davis JD, Bansal A, Hassman D, Akinlade B, Li M, Li Z, Swanson B, Hamilton JD, DiCioccio AT.

Clin Pharmacol Ther. 2018 Dec;104(6):1146-1154. doi: 10.1002/cpt.1058. Epub 2018 Apr 2.

19.

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).

de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L, Hultsch T, Chen Z, Pirozzi G, Graham NMH, Shumel B.

Br J Dermatol. 2018 May;178(5):1083-1101. doi: 10.1111/bjd.16156. Epub 2018 Mar 25.

20.

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B.

Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.

PMID:
28478972
21.

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Simpson EL, Akinlade B, Ardeleanu M.

N Engl J Med. 2017 Mar 16;376(11):1090-1. doi: 10.1056/NEJMc1700366. No abstract available.

PMID:
28296614
22.

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators.

N Engl J Med. 2016 Dec 15;375(24):2335-2348. Epub 2016 Sep 30.

23.

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients.

Zhu T, Keirns J, Howieson C, Kaibara A, Goldwater R, Kivitz AJ, Chindalore V, Cohen S, Santos V, Akinlade B, Kernstock R, Delgado-Herrera L, Blahunka PC, Karrer EE, Garg JP, Samberg N, Zeiher BG.

Clin Pharmacol Drug Dev. 2016 Sep;5(5):408-25. doi: 10.1002/cpdd.251. Epub 2016 Mar 28.

PMID:
27410490
24.

Overview of radiation dose to patients from medical X-ray examinations in Nigeria.

Akinlade BI, Odefemi FB, Farai IP.

Afr J Med Med Sci. 2016 May;45(1):23-29.

PMID:
28686825
25.

Comparison of doses to the rectum derived from treatment planning system with in-vivo dose values in vaginal vault brachytherapy using cylinder applicators.

Oyekunle EO, Obed RI, Akinlade BI, Ntekim A.

J Contemp Brachytherapy. 2015 Dec;7(6):485-91. doi: 10.5114/jcb.2015.56767. Epub 2015 Dec 30.

26.

Radiation therapy interruption in a poor resource setting: causes and management..

Akinlade BI, Folasire AM, Elumelu-Kupoluyi TN, Adenipekun AA, Iyobosa UB, Campbell OB.

Afr J Med Med Sci. 2014 Dec;43(4):333-7.

PMID:
26234121
27.

A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.

Papp K, Pariser D, Catlin M, Wierz G, Ball G, Akinlade B, Zeiher B, Krueger JG.

Br J Dermatol. 2015 Sep;173(3):767-76. doi: 10.1111/bjd.13745. Epub 2015 Jun 19.

PMID:
25704750
28.

Survey of dose area product received by patients undergoing common radiological examinations in four centers in Nigeria.

Akinlade BI, Farai IP, Okunade AA.

J Appl Clin Med Phys. 2012 Jul 5;13(4):3712. doi: 10.1120/jacmp.v13i4.3712.

29.

Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.

Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W.

Diabetes Technol Ther. 2011 Dec;13(12):1219-27. doi: 10.1089/dia.2011.0012. Epub 2011 Aug 19.

PMID:
21854192
30.

Gamma camera intrinsic uniformity in an unstable power supply environment.

Ejeh JE, Adedapo KS, Akinlade BI, Osifo BO.

Hell J Nucl Med. 2011 May-Aug;14(2):146-8.

PMID:
21761017
31.

Liquisolid systems to improve the dissolution of furosemide.

Akinlade B, Elkordy AA, Essa EA, Elhagar S.

Sci Pharm. 2010 Apr-Jun;78(2):325-44. doi: 10.3797/scipharm.0912-23. Epub 2010 Apr 23.

32.
33.

Pattern of paediatric malignancies seen at the Radiotherapy Department of the University College Hospital, Ibadan, Nigeria.

Abdus-salam AA, Adenipekun AA, Akinlade BI, Elumelu TN.

Nig Q J Hosp Med. 2007 Oct-Dec;17(4):152-4.

PMID:
18320762
34.

Molecular characterization of Staphylococcus aureus isolates from a 2005 clinical trial of uncomplicated skin and skin structure infections.

Jones RN, Nilius AM, Akinlade BK, Deshpande LM, Notario GF.

Antimicrob Agents Chemother. 2007 Sep;51(9):3381-4. Epub 2007 Jun 18.

35.

Cefdinir vs. cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults.

Giordano PA, Elston D, Akinlade BK, Weber K, Notario GF, Busman TA, Cifaldi M, Nilius AM.

Curr Med Res Opin. 2006 Dec;22(12):2419-28.

PMID:
17257456
36.

Efficacy, tolerability, and parent reported outcomes for cefdinir vs. high-dose amoxicillin/clavulanate oral suspension for acute otitis media in young children.

Block SL, Schmier JK, Notario GF, Akinlade BK, Busman TA, Mackinnon GE 3rd, Halpern MT, Nilius AM.

Curr Med Res Opin. 2006 Sep;22(9):1839-47.

PMID:
16968587
37.

Advanced cervical carcinoma in Ibadan, Nigeria: an appraisal of radiation therapy.

Campbell OB, Arowojolu AO, Akinlade BI, Adenipekun A, Babarinsa IA.

J Obstet Gynaecol. 2000 Nov;20(6):624-7.

PMID:
15512681
38.

Aspirin, clopidogrel, or both for secondary prevention of coronary disease.

Akinlade BK.

N Engl J Med. 2003 Feb 6;348(6):560-3; author reply 560-3. No abstract available.

39.

Comparison of entrance surface doses of some X ray examinations with CEC reference doses.

Ogunseyinde AO, Adeniran SA, Obed RI, Akinlade BI, Ogundare FO.

Radiat Prot Dosimetry. 2002;98(2):231-4.

PMID:
11930883

Supplemental Content

Loading ...
Support Center